Clincosm LogoSign in Get a demo

Gastro-enteropancreatic Neuroendocrine Tumor

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors Trial in Iowa City (Lutathera, Azedra)

Not yet recruiting
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Neuroendocrine Tumors
  • Iowa City, Iowa
    Holden Comprehensive Cancer Center
Jul 7, 2022

Gastro-enteropancreatic Neuroendocrine Tumor Trial (Pasireotide, Diazoxide)

Withdrawn
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • (no location specified)
Feb 17, 2022

Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma Trial in France (Phase 1 : Regorafenib,

Recruiting
  • Colorectal Cancer Not MSI-H or MMR-deficient
  • +9 more
  • Phase 1 : Regorafenib
  • +4 more
  • Bordeaux, France
  • +6 more
Dec 6, 2021

Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor Trial in Taiwan (CVM-1118)

Recruiting
  • Neuroendocrine Tumors
  • +4 more
  • Kaohsiung, Taiwan
  • +6 more
Aug 24, 2021

Gastro-Enteropancreatic Neuroendocrine Tumor Trial in Austria, Denmark, United States (Satoreotide trizoxetan 5-20µg,

Completed
Has Results
  • Gastro-Enteropancreatic Neuroendocrine Tumor
  • Satoreotide trizoxetan 5-20μg
  • Satoreotide trizoxetan 30-45μg
  • Los Angeles, California
  • +4 more
Jan 8, 2021

The Lyon Real World Evidence in Metastatic NeuroEndocrine

Unknown status
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • +2 more
  • Metastatic gastroenteropancreatic and lung neuroendocrine tumors
  • Lyon, France
    Hospices Civils de Lyon
Mar 4, 2019